Medical Director: Alexandra Drakaki, MD
According to the American Cancer Society, about 73,510 people in the United States will be diagnosed with kidney cancer (55,600 Male and 17,910 Female) in 2012 and about 14,880 people will die from this disease (10,510 Male and 4,370 Female). Bladder cancer is the fifth most common cancer overall, the fourth most common in men and the eighth most common in women.
The IUO and UCLA's Bladder Cancer Program offer a multidisciplinary comprehensive program offering the latest treatments and compassionate care. Patients of the IUO again have the benefit of our long-held team approach to the treatment of bladder cancer that includes world-class urologic oncologists, medical oncologists, radiation oncologists, pathologists, radiologists and our clinical trial's team of physicians and nurses.
- Detailed Clinical Information on Bladder Cancer »
- Bladder Cancer Experts »
- Clinical Trials & Research at UCLA »
Highlights: Research & Achievements at UCLA Bladder Cancer Program
- In the 1980's, initiation of a clinical trial of BCG bladder irrigation for superficial bladder tumors; it constituted one of the early studies confirming the role of BCG in the treatment of carcinoma in situ of the bladder.
- Identification of some of the first monoclonal antibodies in bladder cancer and, by confirming their selective binding to bladder tumor sites, confirmation of their potential utility in the diagnosis and treatment of bladder cancer.
- Development and application of pioneering bladder-reconstruction surgical techniques during the last 20 years, establishing UCLA's important role in bladder reconstruction using an ileocecal reservoir.
- June 2000 completion of UCLA's bladder cancer tissue microarrays, comprising 3,128 samples involving 545 cases from 387 patients; these arrays were integrated with UCLA Institutional Review Board approval to a linked bladder cancer clinicopathological database and are now being used to identify and evaluate molecular markers in bladder cancer.
- Awarding of an NCI $7 million multidisciplinary grant and cancer prevention clinical trial of green tea and an epidermal growth factor receptor (EGRr) antagonist.